Statement of Principles concerning malignant neoplasm of the brain (Balance of Probabilities) (No. 18 of 2026)

Definitions and a small set of operational thresholds are the main concepts that determine how the Statement functions.

• The condition covered. Malignant neoplasm of the brain is defined positively and negatively in s7(2). It must be a primary malignant tumour arising from brain cells. It explicitly includes malignant neuroepithelial tumours and germ cell tumours, and excludes a non‑exhaustive list of other neoplasms and tumour types (for example, central nervous system lymphomas, meningiomas, schwannomas and pituitary adenomas are excluded). The Schedule cross‑references and expands “neuroepithelial tumour” to a list of subtypes (Schedule 1).

• Causation standard and RMA view. The RMA states that, on the available medical‑scientific evidence, it is more probable than not that malignant neoplasm of the brain can be related to relevant service (s8). The Statement then sets the factors that “must exist” before a tribunal or decision‑maker can conclude connection on the balance of probabilities (s9).

• Two disjunctive factual factors. A single qualifying factor suffices, provided it is related to relevant service (s9(1)-(2); s10(1)). The factors are: (1) cumulative equivalent radiation dose to the brain of at least 0.5 sievert received at least two years before clinical onset (s9(1)(a)); or (2) inability to obtain appropriate clinical management for the malignant neoplasm before clinical worsening (s9(1)(b)). The radiation factor sets a numeric dose threshold and a minimum latency period. The clinical‑management factor is non‑numeric and depends on comparative clinical circumstances.

• Relationship to relevant service. The factors must be connected to the person’s relevant service, as that term is defined in the Schedule. The clinical‑management factor has a specific application to material contribution or aggravation of pre‑existing disease: it applies only where the person’s malignant neoplasm was suffered or contracted before or during, but did not arise out of, the relevant service (s10(2)).

• Dose measurement methodology and exclusions. “Cumulative equivalent dose” is defined in the Schedule and must be calculated in accordance with the ARPANSA guide referenced “as in force on 2 August 2017” and excludes normal background radiation exposure in Australia (Schedule 1). The Schedule emphasises that dose calculations should be averaged over the mass of the specific tissue or organ and combined when multiple radiation sources are involved.

• Interaction with other Statements. If a factor in this Statement refers to an injury or disease covered by another Statement of Principles made under subsection 196B(3) of the VEA, the factors in that other Statement apply as in force from time to time (s11). That creates an explicit mechanism for cross‑reference where a causal pathway involves other conditions covered by separate SOPs.

• Inclusion of death. Death from a terminal event or condition contributed to by the malignant neoplasm is included in the meaning of the disease for the purposes of claims (s7(5)); the Schedule gives examples of “terminal event” (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).

These concepts combine a deterministic numeric element (dose threshold and latency), a discretionary clinical element (appropriateness of management and clinical worsening), definitional boundaries (the list of inclusions and exclusions), and a method link to an external technical guide for dose reconstruction. The Schedule’s definitions therefore play a central role in interpreting the textual factors set out in s9 and s10.

This instrument affects three categories of stakeholders in the veterans’ compensation ecosystem by changing the medical causation framework used in claims for malignant neoplasm of the brain.

• Claimants and potential claimants. The instrument applies to persons lodging claims to which section 120B of the VEA or section 339 of the MRCA applies (s5). Those persons will be required to show a factor in s9 that is related to their “relevant service” as defined in the Schedule. “Relevant service” is defined narrowly: eligible war service other than operational service under the VEA, defence service other than hazardous service and British nuclear test defence service under the VEA, or peacetime service under the MRCA (Schedule 1). The specific exclusions in that definition may narrow the pool of service types that can generate a connection under this Statement. Individuals who allege exposure in circumstances specifically excluded from “relevant service” will need to analyse whether their exposure nonetheless falls within the defined categories.

• Medical and technical assessors. The Repatriation Medical Authority made the instrument under s196B(3) of the VEA (s3). Medical practitioners and technical experts preparing evidence, and the department’s medical officers or independent medical examiners, will need to apply the definitions and thresholds here. For radiation cases they must use the ARPANSA guide “as in force on 2 August 2017” for calculation of cumulative equivalent dose (Schedule 1). The guide is the mandatory methodology for dose reconstruction for this Statement; assessors must take account of the Schedule’s instruction that dose is averaged over mass and that multiple sources must be combined.

• Decision‑makers and administrators. Departmental officers, review bodies and other decision‑makers who determine eligibility under the VEA and MRCA will use this Statement as their medical causation framework. The instrument informs but does not itself grant entitlement: it prescribes the causation factors which, if established and related to relevant service, support a finding that the condition is connected with service (s9; s10). Decision‑makers must also consider cross‑references to other Statements where a factor mentions a condition covered by another SOP (s11).

• Service organisations and legal representatives. Organisations that advise or represent veterans will need to align evidence gathering and case theory to the two alternative factors: either demonstrating cumulative equivalent dose above 0.5 sievert with appropriate latency or establishing inability to obtain appropriate clinical management before clinical worsening. The Schedule’s examples of exposure circumstances (presence during or after nuclear testing, medical procedures, aircrew cosmic radiation exposure) are relevant to claims strategy, but the Statement’s “relevant service” definition will determine whether those exposure circumstances operate in the claimant’s legal nexus to service.

• Public health and radiation monitoring entities. The instrument anchors dose reconstruction to an ARPANSA guide. Entities that hold records of radiation exposure, or that perform dose reconstructions, will be relevant sources of evidence. The Schedule’s exclusion of normal background radiation and its instruction on averaging dose over tissue mass impose technical obligations on dose estimators.

Who does not benefit automatically: persons whose tumours fall within the express exclusions listed in s7(2) are outside the scope of this Statement. Also, the “relevant service” definition excludes certain categories of service, which may exclude particular exposure cohorts from the Statement’s assistance. The instrument itself contains no provision for benefits or payment; it shapes the causation assessment used in statutory claims under the VEA and MRCA.

The Statement establishes evidentiary factors and definitional limits rather than prescriptive administrative duties or statutory entitlements. Nevertheless it creates binding obligations and recognised rights in the decision‑making process by determining what must be shown for causation in claims under the VEA and MRCA.

• Duty to use the Statement in claim assessments. Because the instrument is made under subsection 196B(3) of the VEA (s3), decision‑makers using the SOP framework for assessing claims under section 120B of the VEA or section 339 of the MRCA are required to have regard to the Statement’s factors when determining whether malignant neoplasm of the brain is connected with service (s5). The Statement supplies the factors that “must exist” for causation to be accepted (s9).

• Duty to adhere to the Schedule’s methodology for dose calculation. If a claimant relies on the radiation factor, the cumulative equivalent dose must be calculated “in accordance with the methodology set out in” the specified ARPANSA guide “as in force on 2 August 2017” (Schedule 1). This imposes a technical duty on those producing dose estimates to use that exact edition and methodology for the purposes of the Statement. The Schedule also makes clear that normal background radiation exposure in Australia is to be excluded from the cumulative equivalent dose calculation.

• Right to rely on either disjunctive factor. The Statement gives claimants two alternative pathways to establish connection: either meet the radiation threshold and latency, or establish inability to obtain appropriate clinical management before clinical worsening (s9). Establishing either factor, if related to relevant service, is sufficient under the Statement for causal connection on the balance of probabilities.

• Duty to relate the factor to relevant service. The Statement requires that any factor relied upon must be related to the person’s relevant service (s10(1)). The Schedule’s definition of relevant service therefore circumscribes the permissible factual link between the factor and service.

• Limitation on the clinical‑management factor. The clinical‑management factor (s9(1)(b)) applies only to cases involving material contribution or aggravation, specifically where the person’s malignant neoplasm was suffered or contracted before or during, but did not arise out of, relevant service (s10(2)). That means the clinical‑management factor cannot be used to establish primary causation when the disease arose out of service; it is aimed at pre‑existing conditions that were materially contributed to or aggravated by service because of lack of management.

• Interaction duty where other SOPs apply. If a factor in this Statement refers to an injury or disease covered by another Statement of Principles, then the factors in that other Statement apply in accordance with its terms as in force from time to time (s11). Decision‑makers must therefore cross‑check relevant SOPs and apply those Statements’ terms where overlap exists.

• Right to have death included. The instrument explicitly includes death from a terminal event or condition that was contributed to by the malignant neoplasm of the brain (s7(5)). This means that claims for death where a terminal event was contributed to by the tumour fall within the Statement’s scope.

What the Statement does not do. It does not itself create entitlement or procedural rights beyond shaping the causation analysis. It does not define evidentiary rules, appeal routes or benefit levels; those matters remain for the VEA, the MRCA and the decision‑making apparatus that applies them. Nor does it define “appropriate clinical management” or “clinical worsening”, leaving those concepts to clinical judgement and the decision‑maker’s assessment of medical evidence.

The instrument is not a penal statute and contains no criminal offences, civil penalties, or enforcement mechanisms within its text. Its effect is administrative and evidentiary; enforcement occurs indirectly through its use by statutory decision‑makers under the VEA and the MRCA.

• No direct sanctions in the Statement. The Statement contains no penalising provisions and does not impose fines, imprisonment, licensing sanctions or other direct penalties. It does not create obligations enforceable by regulatory fines or criminal prosecution. Its legal force lies in the statutory authority of the Repatriation Medical Authority to determine Statements of Principles under subsection 196B(3) of the VEA (s3), which then inform decision‑making under the VEA and MRCA.

• Administrative consequences mediated by VEA/MRCA processes. Because the Statement dictates the factors decision‑makers must consider when assessing causation for claims governed by section 120B of the VEA or section 339 of the MRCA (s5), the practical “enforcement” effect is that a claimant who cannot establish a factor related to relevant service will be at risk of having their claim rejected on causation grounds. Conversely, a claimant who establishes a qualifying factor related to relevant service will have medical causation established under the SOP and can then proceed to entitlement determinations under the VEA or MRCA. The Statement therefore influences outcomes in administrative decisions, which themselves may carry consequences such as award, denial or review of benefits under the parent statutes.

• Role of medical and technical evidence. The Schedule requires the use of a technical methodology for dose calculations (Schedule 1). If dose reconstructions fail to meet the Schedule’s requirements or are inconsistent with the ARPANSA methodology specified, decision‑makers can discount such evidence when applying the Statement. There is no internal enforcement mechanism in the Statement to compel particular parties to produce compliant dose reconstructions; rather, the admissibility and weight of evidence are matters for the adjudicating authority.

• No internal inspection or compliance regime. The instrument does not establish an inspection, monitoring or compliance regime tied to service providers or employers. It prescribes a standard for evidentiary assessment in claims, not a compliance enforcement apparatus outside the veterans’ compensation framework.

In summary, the Statement does not create penalties or enforcement mechanisms; its practical effect is to bind decision‑makers to particular causation thresholds and methodologies that will determine whether administrative outcomes under the VEA and MRCA can be reached in favour of a claimant.

The Statement is an instrument under the Veterans’ Entitlements Act 1986 and is intended to operate within the decision‑making architecture of the VEA and the Military Rehabilitation and Compensation Act 2004. It interacts with those statutes and with other Statements of Principles in specific, limited ways set out in the text.

• Primary statutory hook. The instrument is made under subsection 196B(3) of the VEA (s3). It applies to claims to which section 120B of the VEA or section 339 of the MRCA applies (s5). That places the Statement squarely within the statutory machinery that governs medical causation in veterans’ compensation claims. It does not itself alter the substantive provisions of the VEA or MRCA; instead it provides the medical causation factors that decision‑makers under those Acts must rely on.

• Integration with other Statements of Principles. Section 11 requires that where a factor in this Statement refers to an injury or disease that is the subject of another Statement of Principles made under subsection 196B(3) of the VEA, the factors in that other Statement apply in accordance with its terms as in force from time to time. That cross‑reference creates a mechanism for multi‑factor causation pathways to be resolved by applying the relevant SOPs together. Practically, decision‑makers must identify overlapping SOP coverage and apply the most relevant factors from each Statement.

• External technical methodology. The Schedule incorporates an external technical standard by reference: the ARPANSA guide to calculation of “cumulative equivalent dose” as in force on 2 August 2017 (Schedule 1). This creates an interaction with non‑statutory technical publications and entities that produce dose reconstruction methodologies. The choice to fix the methodology to a specific edition embeds that external document as part of the legal test for radiation exposure factors.

• Relationship to ICD coding. The Statement notes that malignant neoplasm of the brain attracts ICD‑10‑AM code C71, but the meaning of the condition for this Statement is as given in the instrument itself (s7(4)). That means ICD coding is informative but not decisive; the statutory definition in s7(2) controls.

• Service definitions and exclusions. The Schedule’s definition of “relevant service” interacts with the VEA’s and MRCA’s categories of service and will affect which service records and historical circumstances can be asserted as the connecting service. The Schedule excludes certain specified categories from “relevant service” (for example, British nuclear test defence service is excluded from the defence service category as defined), which may interact with other statutes, historical entitlements or specific legislative schemes that deal with nuclear test participants.

• No amendment to benefit law. The Statement does not change the substantive criteria for entitlement that are set out in the VEA and MRCA; it sets out the medical causation framework that will be used when courts or administrative decision‑makers apply those statutes. Entitlement, rates and procedural rights remain governed by the parent Acts.

• Procedural or review mechanisms not supplied. The Statement does not create or modify appeal, review or procedural mechanisms; any such rights of review or appeal will be those provided by the VEA and MRCA and their implementing regulations.

Overall, interaction is directional: this instrument feeds into VEA/MRCA claim assessments and cross‑references other SOPs, while drawing on an external technical guide for dose calculation. It does not create new statutory entitlement or procedural pathways outside the established Acts.

The instrument contains limited explicit amendment history in its text and indicates a direct repeal of an earlier Statement of Principles.

• Repeal of the 2016 Statement. Section 4 expressly repeals the Statement of Principles concerning malignant neoplasm of the brain (Balance of Probabilities) (No. 86 of 2016) (Federal Register of Legislation F2016L01693) made under subsection 196B(3) of the VEA. That is the only repeal or amendment recorded in this instrument. The 2026 instrument therefore replaces the 2016 Statement for all purposes from commencement.

• Commencement. The instrument commences on 23 March 2026 (s2). From that date the 2016 Statement is repealed and the No. 18 of 2026 Statement operates for claims to which it applies (s4; s2).

• Fixed external methodology edition date. The Schedule specifies that the ARPANSA guide to calculation of cumulative equivalent dose is to be used “as in force on 2 August 2017” (Schedule 1). This is a form of legislative locking to a particular edition of an external technical document. It means that, unless this Statement is itself amended, later revisions of that ARPANSA guide will not automatically alter the dose‑calculation standard for this Statement.

• No other amendments recorded. The instrument contains no other amending or savings provisions, transitional arrangements, or modifications to the VEA or MRCA themselves. It neither amends other SOPs nor records subsequent amendments to this Statement. Any future change would presumably be by a further instrument made under subsection 196B(3) of the VEA, but no amendment history beyond the repeal of the 2016 Statement is recorded within the text.

Practitioners should therefore note that the 2016 Statement has been expressly removed and replaced by this 2026 instrument from the stated commencement date, and that the ARPANSA methodology citation is fixed to the specified date. Any evidence or submissions prepared under the 2016 Statement will need to be revisited to ensure compliance with the definitions, exclusions and the methodology specified in the 2026 Statement.

The Statement itself does not recite any litigation history, and it names no case law. The instrument is a Repatriation Medical Authority determination and contains no references to judicial decisions or prior litigation. Therefore, within the text of the instrument there is no litigation history to report.

Although the instrument is silent on litigation, factual and legal issues that may be prone to dispute, as framed by the Statement, include:

• Definitional boundary disputes. The instrument lists specific inclusions and exclusions for malignant neoplasm of the brain (s7(2)). Disputes between parties about whether a particular tumour falls inside or outside that statutory definition could generate litigation, especially where pathology or diagnostic terminology is contested. For example, a tumour categorised clinically as a meningioma is expressly excluded; litigated disputes could arise where tumour classification is ambiguous. The instrument itself does not provide adjudicative mechanisms for those definitional disputes beyond their application in claims under the VEA and MRCA.

• Radiation dose reconstruction methodology. The Schedule requires dose calculation in accordance with an ARPANSA guide as in force on 2 August 2017. Litigation could arise over the application of that methodology, the quality of available exposure records, the assumptions in dose reconstructions, and whether cumulative equivalent dose excluding background meets or fails the 0.5 sievert threshold and the two year latency requirement (s9(1)(a); Schedule 1). The Statement’s locking of the methodology to a particular edition may be a particular flashpoint where experts disagree about whether methods not embodied in that edition should be considered.

• Clinical management standard vagueness. The clinical‑management factor (s9(1)(b)) is qualitatively expressed. The Statement does not define “appropriate clinical management” or “clinical worsening”, which leaves these concepts to medical evidence and administrative judgement. That openness is a potential locus of dispute and may invite litigation where claimants contend that lack of access to treatment during service materially contributed to progression, and decision‑makers find otherwise.

• Service connection disputes. The Schedule defines “relevant service” narrowly and explicitly excludes certain service types (Schedule 1). Litigation could arise where claimants assert that their service falls within the Schedule’s categories and decision‑makers disagree; or where exposure occurred outside the Schedule’s defined categories but claimants seek to connect exposures through other legal or factual theories.

• Cross‑SOP boundary issues. Section 11 requires application of factors in other Statements where overlap exists. Litigation may follow where claimants and decision‑makers dispute which SOP governs a particular factor or how multiple SOPs should be applied together.

The instrument does not itself indicate how these disputes have been resolved historically or whether there is an established body of case law on these particular issues. Any litigation arising from application of this Statement will occur in the context of disputes about administrative decisions under the VEA and MRCA, and any judicial review or merits review would rely on the statutory provisions and administrative law principles external to this instrument. Within the instrument there are no named cases and no litigation history to cite.

This Section flags specific textual and operational traps that follow directly from the instrument’s language and definitions. Each is grounded in the instrument and may affect claim strategy and evidence preparation.

• Reliance on ICD codes is limited. The instrument notes that malignant neoplasm of the brain attracts ICD‑10‑AM code C71, but then states that for the purposes of the Statement the meaning is as given in s7(2) (s7(4)). In practice this means that a claimant cannot succeed by relying on ICD code labelling alone; the tumour must match the Statement’s positive and negative definitions.

• Narrow and unusual definition of “relevant service”. Schedule 1 defines “relevant service” in a way that excludes some service types. Notably, defence service excludes hazardous service and British nuclear test defence service. The Schedule also separates eligible war service and peacetime service in particular ways. A claimant who served in a context commonly associated with radiation exposure, such as British nuclear test participation, may find that the Schedule’s definition excludes that service from being “relevant service” for the purposes of this Statement. The Schedule’s inclusion of examples of circumstances that might lead to exposure (e.g., nuclear testing participation) should not be read to expand the statutory definition of relevant service. Always cross‑check the person’s service category against the Schedule.

• Dose threshold excludes background radiation. “Cumulative equivalent dose” excludes normal background radiation exposure in Australia (Schedule 1). Practically, this requires subtraction of background when estimating dose. Many dose estimates reported in occupational health literature include background; evidence must be adjusted to match the Statement’s definition or will not meet the statutory test.

• Methodology locked to a specific ARPANSA guide edition. The Schedule requires calculation “in accordance with the methodology set out in” the ARPANSA guide “as in force on 2 August 2017”. If dose reconstruction methods have evolved since that date, updated scientific techniques will not, by themselves, change the legal test unless the Statement is amended. Experts who use later methodologies may need to produce a parallel calculation using the 2017 edition to meet the Statement’s requirement.

• Latency and timing are strict. The radiation factor requires receipt of at least 0.5 sievert “at least 2 years before the clinical onset of malignant neoplasm of the brain” (s9(1)(a)). The time of “clinical onset” will be contested where symptoms are vague or where diagnosis lag exists. The claimant must be able to produce evidence fixing the onset date against which the two‑year latency is measured.

• Averaging over tissue mass and combining sources. The Schedule instructs that dose is calculated as an average over the mass of a specific tissue or organ and that multiple sources must be combined. Experts who provide whole‑body dose estimates without organ‑specific averaging may produce evidence that is not technically aligned with the Schedule, risking that the calculation will be rejected for not following the required method.

• Clinical‑management factor limited to pre‑existing disease aggravated by service. Section 10(2) restricts the application of s9(1)(b) so it applies only to material contribution or aggravation where the tumour was suffered or contracted before or during service but did not arise out of service. It is not available for primary causation where the disease first arose as a result of service. Claimants and advisers must identify whether the clinical history fits within that temporal limitation.

• “Appropriate clinical management” and “clinical worsening” are undefined. The Statement does not define these terms, leaving them to clinical evidence and judgement. This lack of definition is an evidentiary risk: outcomes may depend heavily on the framing of medical expert opinions and on the decision‑maker’s view of what treatment was reasonable or available.

• Exclusion list may exclude morphologic variants. The Statement excludes specific tumour types by name. In practice, modern pathology sometimes yields mixed or borderline histologies; claimants where pathology is ambiguous will face definitional disputes that can be decisive.

• The Statement does not create entitlement or procedural rights. Because the instrument is an evidentiary framework only, claimants who establish a qualifying factor still must obtain entitlement under the VEA or MRCA; proving the Statement’s factor is necessary for causation but not sufficient for an ultimate award. Legal advisers must manage claimant expectations accordingly.

• Interaction with other SOPs may complicate evidence. Section 11 requires application of other SOPs where overlap exists. That can create multi‑disciplinary evidence requirements and timing issues where multiple SOPs have differing methodologies or definitions.

Each “gotcha” above derives from explicit text in the Statement or the Schedule. Practitioners should plan evidence strategies that directly engage the Schedule’s technical requirements and the Statement’s temporal and definitional constraints.

Compliance, in this context, means preparing evidence and submissions that meet the Statement’s definitional and methodological requirements so that decision‑makers applying the VEA or MRCA can find a qualifying factor related to relevant service.

1. Confirm condition falls within the Statement’s definition. Begin by reviewing the pathological and diagnostic record to ensure the tumour is a primary malignant neoplasm of the brain as defined in s7(2). Check inclusions (malignant neuroepithelial tumour, germ cell tumour) and the exclusions list. If pathology labels are ambiguous or mixed, obtain expert histopathology review that directly addresses whether the disease matches the Statement’s statutory definition.

2. Determine which causation pathway to pursue. The Statement provides two alternative factors in s9. Decide whether the case will rely on: (a) radiation exposure meeting the cumulative equivalent dose and latency criteria, or (b) inability to obtain appropriate clinical management before clinical worsening, typically for pre‑existing disease aggravated by service. The choice affects the type of evidence required.

3. For radiation cases, reconstruct dose per the Schedule. If pursuing the radiation factor under s9(1)(a):

   • Commission a dose reconstruction that explicitly follows the ARPANSA guide named in Schedule 1 “as in force on 2 August 2017”. The Schedule makes this methodology mandatory for the purpose of the Statement.
   • Ensure the dose estimate is for the brain tissue specifically, calculated as an average over the mass of that tissue or organ (Schedule 1).
   • Exclude normal background radiation exposure in Australia from the cumulative equivalent dose calculation, as required by Schedule 1.
   • Combine doses from multiple sources when applicable, and document assumptions used to combine and average.
   • Demonstrate that the cumulative equivalent dose to the brain was at least 0.5 sievert and that the exposure occurred at least two years before clinical onset (s9(1)(a)).

4. Fix the date of clinical onset. The latency calculation requires a reliable date for “clinical onset”. Assemble contemporaneous medical records, GP notes, diagnostic imaging dates, pathology report dates and any other documentation that can anchor the onset date. Where onset date is disputed, provide clear expert opinion explaining how the date was determined and why earlier nonspecific symptoms do not shift onset.

5. For clinical‑management cases, document absence of appropriate treatment and timing. If relying on s9(1)(b):

   • Produce contemporaneous service medical records showing attempts to obtain clinical management, denials, delays, absence of referral, or other circumstances amounting to inability to obtain appropriate management prior to clinical worsening.
   • Provide expert clinical evidence that links the lack of timely or appropriate management to clinical worsening, and demonstrate that the tumour was suffered or contracted before or during relevant service but did not arise out of it (s10(2)). The Statement limits s9(1)(b) to material contribution or aggravation of pre‑existing disease.
   • Where appropriate, document alternative treatment options (or lack thereof) available in the civilian system at the time, to contextualise “inability to obtain appropriate clinical management”.

6. Establish relation to relevant service. For either pathway, assemble service records, deployment records, occupational exposure logs, flight rosters (for aircrew), diagnostic or therapeutic procedure records performed during service, and contemporaneous statements that tie the exposure or lack of management to the person’s defined “relevant service” (s10(1); Schedule 1). Carefully confirm that the service category fits the Schedule’s definition of “relevant service”: eligible war service (other than operational), defence service (other than hazardous and British nuclear test defence service), or peacetime service under the MRCA.

7. Anticipate definitional exclusions. If a tumour sits near an exclusion listed in s7(2), obtain pathology and clinical expert opinion that directly addresses whether the tumour falls within the Statement’s definition despite nomenclature ambiguities. Where pathology reports use terms in the exclusion list, be prepared to argue on diagnostic grounds why those labels do or do not fall within s7(2).

8. Prepare dual calculations if newer methods exist. If experts prefer newer dose‑reconstruction methods post‑dating 2 August 2017, instruct them to also perform and document a parallel calculation using the ARPANSA guide edition locked into the Schedule. The Statement requires the 2017 methodology; presenting both calculations clarifies conformity while showing current scientific practice.

9. Cross‑check other Statements of Principles. Where the causal pathway involves another condition addressed by a separate SOP, identify that SOP and apply its factors as required by s11. Prepare evidence that aligns with both Statements’ requirements where overlap occurs.

10. Tailor expert evidence to statutory language. Expert reports should directly address the statutory elements: whether the cumulative equivalent dose meets or exceeds 0.5 sievert for the brain excluding background, whether exposure occurred at least two years before clinical onset, whether the claimant was unable to obtain appropriate clinical management prior to clinical worsening, and whether any factor is related to relevant service. Experts should refer to the ARPANSA guide when addressing dose and explain the technical steps used to comply with the Schedule’s instructions.

11. Use documentary contemporaneity. The Statement’s time and technical thresholds make contemporaneous records highly probative. Prioritise obtaining service medical files, diagnostic imaging originals, radiation monitoring records, personnel rosters and any records that document denials or limitations of clinical care during service.

12. Be explicit about scope and limitations in submissions. Explain in application materials which Statement factor is relied upon, how the Schedule’s definitions have been satisfied, and why the factor is related to relevant service. Address any exclusions proactively and provide countervailing expert evidence.

Complying with the Statement therefore requires precise technical work, particularly for dose calculations, attentive chronological reconstruction of clinical onset and service exposure, and carefully tailored expert evidence that maps medical findings onto the statutory language in s7, s9, s10 and Schedule 1.